Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Peptide Therapy SummitPeptide Therapy Summit
Not Confirmed
Not Confirmed
03-05 April, 2025
Not Confirmed
Not Confirmed
05-09 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Peptide Therapy SummitPeptide Therapy Summit
Industry Trade Show
Not Confirmed
03-05 April, 2025
Industry Trade Show
Not Confirmed
05-09 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
31 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/31/3052245/0/en/Apollomics-and-LaunXP-Announce-Development-and-Commercialization-Agreement-for-Vebreltinib.html
Details:
under the agreement, LaunXP receives exclusive development and commercialization rights for APL-101 (vebreltinib) in combination with an EGFR inhibitor for the treatment of non-small cell lung cancer.
Lead Product(s): Vebreltinib,Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: APL-101
Study Phase: Phase IIProduct Type: Other Small Molecule
Recipient: Apollomics Inc
Deal Size: $60.0 million Upfront Cash: $10.0 million
Deal Type: Agreement March 31, 2025
Lead Product(s) : Vebreltinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Apollomics Inc
Deal Size : $60.0 million
Deal Type : Agreement
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Details : under the agreement, LaunXP receives exclusive development and commercialization rights for APL-101 (vebreltinib) in combination with an EGFR inhibitor for the treatment of non-small cell lung cancer.
Product Name : APL-101
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
March 31, 2025
ABOUT THIS PAGE